Gregory Piazza, MD, FACC
Physician
Brigham and Women's HospitalHarvard Medical School

Printed as of 11/13/2026

Disclosures

Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Amgen Inc.	Research/Research Grants ‡ *LDL-ALERT*	Significant (>= $5,000)	*Prevention*
Bayer	Research/Research Grants ‡ *CKD-ALERT*	Significant (>= $5,000)	*Prevention*
BMS	Research/Research Grants ‡ *HIPRO Trial, CORONA-VTE Network*	Significant (>= $5,000)	*Vascular Medicine*
BSC	Research/Research Grants ‡ *HI-PEITHO Trial, Pulmonary Vascular Imaging Study*	Significant (>= $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*
CSL Behring	Consultant Fees/Honoraria	Modest (< $5,000)	*Vascular Medicine*
ESPERION	Research/Research Grants ‡ *PAD-ALERT*	Significant (>= $5,000)	*Prevention*
Janssen Pharmaceuticals, Inc	Research/Research Grants ‡ *PREVENT-HD*	Significant (>= $5,000)	*Vascular Medicine*
NAMSA	Data Safety Monitoring Board	Modest (< $5,000)	*Vascular Medicine*
Pfizer	Consultant Fees/Honoraria	Modest (< $5,000)	*Vascular Medicine*
Regeneron	Research/Research Grants ‡ *ROXI-CATH*	Significant (>= $5,000)	*Vascular Medicine*
Spouse/Domestic Partner/Immediate Household Member			
BSC- GI/ENDOSCOPY	Salary	Significant (>= $5,000)	*Other*

Additional Personal Commercial Disclosures for Education Activities (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Brigham and Women's Hospital	Salary	Significant (>= $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*

Personal Organizational or Other Non-Commercial (2)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Penumbra	Consultant Fees/Honoraria	Modest (< $5,000)	*Invasive CV Angio and Interventions*
Thrombolex	Consultant Fees/Honoraria	Modest (< $5,000)	*Invasive CV Angio and Interventions*

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/14/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/14/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/14/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 2/21/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.